Near Infrared Spectroscopy to Determine Patent Ductus Arteriosus Closure

NCT ID: NCT03026192

Last Updated: 2019-01-23

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Total Enrollment

4 participants

Study Classification

OBSERVATIONAL

Study Start Date

2016-12-31

Study Completion Date

2018-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Using cerebral and renal near infrared spectroscopy monitoring to determine PDA closure in preterm infants after completing medical treatment for a hemodynamically significant PDA.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Patent Ductus Arteriosus

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

no PDA

These are infants who do not have a patent ductus arteriosus (PDA) as determine by echocardiography

near infrared spectroscopy

Intervention Type DEVICE

Near infrared spectroscopy will be placed on infants both with and without hsPDA

hsPDA

These are infants who have a hemodynamically significant PDA (hsPDA) as determined by echocardiography

near infrared spectroscopy

Intervention Type DEVICE

Near infrared spectroscopy will be placed on infants both with and without hsPDA

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

near infrared spectroscopy

Near infrared spectroscopy will be placed on infants both with and without hsPDA

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* preterm infants less than 32 weeks gestation

Exclusion Criteria

* infection, congenital heart disease, syndromic anomalies, and perinatal asphyxia.
Minimum Eligible Age

1 Minute

Maximum Eligible Age

1 Week

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Albany Medical College

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Kate Tauber

Assistant Professor

Responsibility Role PRINCIPAL_INVESTIGATOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Albany Medical Center Neonatal Intesive Care Unit

Albany, New York, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

4585

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

PDA Post NICU Discharge
NCT02750228 COMPLETED
Happy Baby Hearts Study
NCT05842876 COMPLETED